Exozymes Inc. (EXOZ) Stock Price & Analysis

Exozymes Inc. (EXOZ) fell 0.16% to USD 6.3 as of September 9, 2026 at 14:00 UTC, according to Nexqual real-time market data.

EXOZ last closed at USD 6.31; the session ranged USD 6.3–6.77 on volume of 2,592 shares. Market capitalization is $58.47M, with a 52-week range of USD 4.35–18.4 (NCM). Source: Nexqual, September 9, 2026 at 14:00 UTC.

Key Statistics (as of September 9, 2026 at 14:00 UTC)

Technical Analysis (EXOZ)

Nexqual's technical model rates EXOZ "NEUTRAL" based on 3 bullish and 3 bearish signals across 128 daily candles, as of September 9, 2026 at 14:00 UTC.

Earnings (EXOZ)

Source: Nexqual, September 9, 2026 at 14:00 UTC.

Financials & Fundamentals (EXOZ)

Source: Nexqual, September 9, 2026 at 14:00 UTC.

Financial Health Score (EXOZ)

Nexqual rates Exozymes Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 14:00 UTC.

Ownership (EXOZ)

Source: Nexqual, September 9, 2026 at 14:00 UTC.

From Exozymes Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• A number of companies are multinational companies, and many are also publicly listed companies, with large market capitalizations.   We believe that we compete with those firms based on a number of factors, including         We also believe eXoZymes will compete based on our unique technological approach.
• In our approach we have integrated artificial intelligence, bioengineering, and biochemical pathway engineering, using feedback loops that utilize our ability to generate high-quality data within a state-of-the-art laboratory setting that allows us to design, test, scale and make biosolutions for commercial use.
• Furthermore, there is a limitation to what kinds of chemical compounds petrochemistry can efficiently produce, as nature is simply much more diverse and complex.   As a best-of-both-worlds solution for future chemical production, eXoZymes believes it has developed technology that will allow us to harness more of the mechanisms that nature uses for biochemical production.
• Because we consider our technology as so foundational, differentiated, and full of potential, we believe existing terminology was insufficient to accurately describe it.

Partnerships

• Through those potential research and development programs we intend to further develop IP that will target the following domains:     Key terms of the license agreement with the Regents of the University of California   On April 26, 2019, we entered into a licensing agreement with The Regents of The University of California, through the University of California, Los Angles ("UCLA").
• There are additional milestone payments due based on net sales equal to $250,000 on the first $1,000,000 of net sales of an initial licensed product and then $350,000 when a second licensed product has $2,000,000 of net sales.       The aggregate of payments made to the Regents in connection with our license agreement with the Regents, from 2019 to December 31, 2025, is $400,211.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:00 UTC. This page is informational and not investment advice.